ascopubs.org

Classification of molecular subtypes of triple-negative breast cancer using reverse phase protein arrays (RPPAs).

Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...
WKRG

VIPC Awards Commonwealth Commercialization Fund Grant to GMU for Reverse Phase Protein Array Software Development

RICHMOND, VIRGINIA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- The Virginia Innovation Partnership Corporation (VIPC) today announced that George Mason ...
Seeking Alpha

Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board

Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (THER), Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase ...
Nasdaq

Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite ...
Morningstar

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Registry expected to pair Ignite’s reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for ...